The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease
Open accessAbstract
Metastatic breast cancer is usually diagnosed after becoming symptomatic, at which point it is rarely curable. Cell-free circulating tumor DNA (ctDNA) contains tumor-specific chromosomal rearrangements that may be interrogated in blood plasma. We evaluated serial monitoring of ctDNA for earlier detection of metastasis in a retrospective study of 20 patients diagnosed with primary breast cancer and long follow-up. Using an approach combining low-coverage whole-genome sequencing of primary tumors and quantification of tumor-specific rearrangements in plasma by droplet digital PCR, we identify for the first time that ctDNA monitoring is highly accurate for postsurgical discrimination between patients with (93%) and without (100%) eventual clinically detected recurrence. ctDNA-based detection preceded clinical detection of metastasis in 86% of patients with an average lead time of 11 months (range 0-37 months), whereas patients with long-term disease-free survival had undetectable ctDNA postoperatively. ctDNA quantity was predictive of poor survival. These findings establish the rationale for larger validation studies in early breast cancer to evaluate ctDNA as a monitoring tool for early metastasis detection, therapy modification, and to aid in avoidance of overtreatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
High-throughput droplet digital PCR system for absolute quantitation of DNA copy number
Hindson, B. J., Ness, K. D., Masquelier, D. A., Belgrader, P., Heredia, N. J., Makarewicz, A. J., Bright, I. J., Lucero, M. Y., Hiddessen, A. L., Legler, T. C., et al. (2011) · Analytical Chemistry · doi:10.1021/ac202028g · Cited by 2,792
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624
Khatcheressian, J. L., Hurley, P., Bantug, E., Esserman, L. J., Grunfeld, E., Halberg, F., Hantel, A., Henry, N. L., Muss, H. B., Smith, T. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9859 · Cited by 626
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
Rack, B., Schindlbeck, C., Jückstock, J., Andergassen, U., Hepp, P., Zwingers, T., Friedl, T. W. P., Lorenz, R., Tesch, H., Fasching, P. A., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju066 · Cited by 615 · cited 2×
“For example, whereas circulating tumor cells (CTCs) may carry additional prognostic information in primary breast cancer (Lucci et al , 2012; Rack et al , 2014), available evidence does not support the use of imaging, serum protein markers, and CTCs for routine monitoring after primary surgery…”
Cited by
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Current and future perspectives of liquid biopsies in genomics-driven oncology
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0071-5 · Cited by 1,557
Liquid biopsy enters the clinic — implementation issues and future challenges
Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Pantel, K., & Alix-Panabières, C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0187-3 · Cited by 1,110
Merker, J. D., Oxnard, G. R., Compton, C., Diehn, M., Hurley, P., Lazar, A. J., Lindeman, N., Lockwood, C. M., Rai, A. J., Schilsky, R. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8671 · Cited by 959
Metadata
- Authors
- Olsson, E., Winter, C., George, A., Chen, Y., Howlin, J., Tang, M. E., Dahlgren, M., Schulz, R., Grabau, D., van Westen, D., Fernö, M., Ingvar, C., Rose, C., Bendahl, P., Rydén, L., Borg, Å., Gruvberger‐Saal, S. K., Jernström, H., & Saal, L. H.
- Venue
- EMBO Molecular Medicine
- Published
- 2015-05-18
- Volume
- 7
- Issue
- 8
- Pages
- 1034-1047
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2116805592
- Cited by
- 453
- References
- 9
- FWCI
- 15.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. https://app.cochat.ai/papers/10.15252/emmm.201404913
- The paper
- Olsson, E., Winter, C., George, A., Chen, Y., Howlin, J., Tang, M. E., Dahlgren, M., Schulz, R., Grabau, D., van Westen, D., Fernö, M., Ingvar, C., Rose, C., Bendahl, P., Rydén, L., Borg, Å., Gruvberger‐Saal, S. K., Jernström, H., & Saal, L. H. (2015). Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201404913
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
